Sanofi to exercise option on third SAFEbody discovery program and sponsor combination clinical trial with muzastotug - ...

Sanofi has agreed to invest up to $25m in Adagene, which will enable the latter to fund its research and development (R&D) ...

Sanofi has doubled down on its partnership with Adagene, investing $25 million in the biotech, taking up its option on a ...

Sanofi's antibody riliprubart has received orphan drug designation (ODD) from Japan's Ministry of Health, Labour and Welfare ...

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is one of the 10 Best Value Stocks to Buy According to Billionaires. Regeneron ...

Sanofi agreed to invest up to $25 million in the clinical-stage biotechnology company. Adagene said it plans to use the proceeds to fund its research and development activities, including clinical ...

Having secured one of last year’s largest funding rounds, AI-focused Formation Bio is now eyeing up 545 million euros ($626 ...

Kymera Therapeutics, Inc.'s stock rose on KT-621 data, but Sanofi's exit casts doubts. A Gilead Sciences, Inc. deal offers ...

Sino-American antibody company Adagene (Nasdaq: ADAG) has announced a strategic investment and option exercise by Sanofi ...

Detailed price information for Adagene Inc ADR (ADAG-Q) from The Globe and Mail including charting and trades.

See the latest Sanofi SA ADR stock price (SNY:XNAS), related news, valuation, dividends and more to help you make your investing decisions.